AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22612171 — intervention group
Group type: COMPARATOR
Intervention: Manipulable objects
Number of subjects: 0
Study 22612171 — intervention group
Group type: COMPARATOR
Intervention: Nonmanipulable objects
Number of subjects: 0
Study 21310287 — intervention group
Group type: EXPERIMENTAL
Intervention: PATH Woman's Condom
Number of subjects: 170
Study 21310287 — intervention group
Group type: EXPERIMENTAL
Intervention: FC2
Number of subjects: 170
Study 21310287 — intervention group
Group type: EXPERIMENTAL
Intervention: V‐Amour
Number of subjects: 170
Study 21310287 — intervention group
Group type: COMPARATOR
Intervention: All condom types
Number of subjects: 170
Study 20134218 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise program below 90 degrees
Number of subjects: 30
Study 20134218 — intervention group
Group type: COMPARATOR
Intervention: Exercise program above 90 degrees
Number of subjects: 30
Study 16923101 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg parecoxib
Number of subjects: 73
Study 16923101 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg parecoxib
Number of subjects: 73
Study 16923101 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 73
Study 15758246 — intervention group
Group type: EXPERIMENTAL
Intervention: Nateglinide (90 mg)
Number of subjects: 36
Study 11423492 — intervention group
Group type: EXPERIMENTAL
Intervention: Low glycemic index dietary advice
Number of subjects: 104
Study 11423492 — intervention group
Group type: COMPARATOR
Intervention: Measured carbohydrate exchange diet (CHOx)
Number of subjects: 104
Study 9390981 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose creatine intake (20 g/day) for 4 days followed by low-dose creatine intake (5 g/day) during 10 weeks of training
Number of subjects: 19
Study 9390981 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose creatine intake (5 g/day) during 10 weeks of training
Number of subjects: 19
Study 9390981 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose creatine intake (5 g/day) during 10 weeks of detraining
Number of subjects: 19
Study 9390981 — intervention group
Group type: EXPERIMENTAL
Intervention: Cessation of creatine intake
Number of subjects: 19
Study 7517058 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprotinin (2 x 10(6) KIU upon anesthetic induction, similar dose in the priming pump, maintenance dose of 500,000 KIU/h)
Number of subjects: 102
Study 7517058 — intervention group
Group type: COMPARATOR
Intervention: Control group (no aprotinin)
Number of subjects: 102
Study 7517058 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (no significant difference)
Number of subjects: 102
Study 3294015 — intervention group
Group type: EXPERIMENTAL
Intervention: Tobramycin
Number of subjects: 62
Study 3294015 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftazidime
Number of subjects: 62
Study 31251716 — intervention group
Group type: EXPERIMENTAL
Intervention: Burch procedure
Number of subjects: 29
Study 31251716 — intervention group
Group type: EXPERIMENTAL
Intervention: Sling procedure
Number of subjects: 29
Study 31251716 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall
Number of subjects: 29
Study 28277865 — intervention group
Group type: EXPERIMENTAL
Intervention: Vortioxetine
Number of subjects: 376
Study 28277865 — intervention group
Group type: COMPARATOR
Intervention: Agomelatine
Number of subjects: 376
Study 28277865 — intervention group
Group type: EXPERIMENTAL
Intervention: Remitters (n=142)
Number of subjects: 376
Study 28277865 — intervention group
Group type: COMPARATOR
Intervention: Nonremitters (n=233)
Number of subjects: 376
Study 25553506 — intervention group
Group type: EXPERIMENTAL
Intervention: Etomidate-remifentanil
Number of subjects: 720
Study 25553506 — intervention group
Group type: COMPARATOR
Intervention: Propofol-remifentanil
Number of subjects: 720
Study 22527327 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal ranibizumab injections (mean number of 5.0 injections) in patients with SMD
Number of subjects: 49
Study 22527327 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal ranibizumab injections (mean number of 4.3 injections) in patients without SMD
Number of subjects: 49
Study 20862628 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized nutritional regimen (ST-Group)
Number of subjects: 99
Study 20862628 — intervention group
Group type: COMPARATOR
Intervention: Individual nutritional regimen (IN-Group)
Number of subjects: 99
Study 18482144 — intervention group
Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 60
Study 18482144 — intervention group
Group type: COMPARATOR
Intervention: Midazolam
Number of subjects: 60
Study 16489473 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (10 mg/day)
Number of subjects: 55
Study 16489473 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study 14629706 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized dose regimen of amitriptyline (n = 30) for 8 weeks
Number of subjects: 60
Study 14629706 — intervention group
Group type: COMPARATOR
Intervention: Empiric dose regimen of amitriptyline (n = 30) for 8 weeks
Number of subjects: 60
Study 11268416 — intervention group
Group type: EXPERIMENTAL
Intervention: Single training trial with olfactory cue and allergen challenge
Number of subjects: 0
Study 11268416 — intervention group
Group type: EXPERIMENTAL
Intervention: Three training trials with olfactory cue and allergen challenge
Number of subjects: 0
Study 11268416 — intervention group
Group type: COMPARATOR
Intervention: Single training trial
Number of subjects: 0
Study 11268416 — intervention group
Group type: EXPERIMENTAL
Intervention: Second test trial
Number of subjects: 0
Study 9010373 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracervical block
Number of subjects: 85
Study 9010373 — intervention group
Group type: COMPARATOR
Intervention: No block
Number of subjects: 85
Study 8093291 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation (60 mg retinol equivalent)
Number of subjects: 55
Study 8093291 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study 2436856 — intervention group
Group type: EXPERIMENTAL
Intervention: Ringer's acetate‐gluconate solution (56 +/- 15 ml/kg)
Number of subjects: 32
Study 2436856 — intervention group
Group type: COMPARATOR
Intervention: 6% dextran‐70 (16 +/- 6 ml/kg)
Number of subjects: 32
Study 31069459 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic yoghurt (100 g/day from 24 weeks of gestation until delivery)
Number of subjects: 130
Study 31069459 — intervention group
Group type: COMPARATOR
Intervention: Conventional yoghurt
Number of subjects: 130
Study 28741134 — intervention group
Group type: EXPERIMENTAL
Intervention: Feeding Buddies programme
Number of subjects: 625
Study 28741134 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 625
Study 28741134 — intervention group
Group type: EXPERIMENTAL
Intervention: Training and community caregiver visit
Number of subjects: 625
Study 27346784 — intervention group
Group type: EXPERIMENTAL
Intervention: Activated photochromic lenses (Gray1, Gray2, Brown)
Number of subjects: 75
Study 27346784 — intervention group
Group type: EXPERIMENTAL
Intervention: Activated photochromic lenses (Gray1)
Number of subjects: 75
Study 27346784 — intervention group
Group type: COMPARATOR
Intervention: Clear polycarbonate lens (control)
Number of subjects: 75
Study 25683276 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran
Number of subjects: 18113
Study 25683276 — intervention group
Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 18113
Study 25683276 — intervention group
Group type: EXPERIMENTAL
Intervention: Transient anemia
Number of subjects: 18113
Study 23780564 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide 25 ug h(‐1)
Number of subjects: 0
Study 23780564 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide 50 ug h(‐1)
Number of subjects: 0
Study 21194827 — intervention group
Group type: EXPERIMENTAL
Intervention: Mefenamic acid (500 mg)
Number of subjects: 141
Study 21194827 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyoscine (10 mg)
Number of subjects: 141
Study 21194827 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 141
Study 18492548 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitting position
Number of subjects: 107
Study 18492548 — intervention group
Group type: COMPARATOR
Intervention: Supine position
Number of subjects: 107
Study 16446007 — intervention group
Group type: EXPERIMENTAL
Intervention: Propionyl l-carnitine (PLC) 2 g/day
Number of subjects: 74
Study 16446007 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 74
Study 12522753 — intervention group
Group type: EXPERIMENTAL
Intervention: Investigational antiretroviral agents
Number of subjects: 0
Study 12522753 — intervention group
Group type: COMPARATOR
Intervention: Highly active antiretroviral therapy (HAART)
Number of subjects: 0
Study 10813126 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronized purified flavonidic fraction plus ispaghula husk
Number of subjects: 162
Study 10813126 — intervention group
Group type: EXPERIMENTAL
Intervention: Rubber band ligation plus ispaghula husk
Number of subjects: 162
Study 10813126 — intervention group
Group type: COMPARATOR
Intervention: Ispaghula husk alone
Number of subjects: 162
Study 8969979 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrine
Number of subjects: 663
Study 8969979 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 663
Study 1589923 — intervention group
Group type: EXPERIMENTAL
Intervention: MFR-guided dilatation
Number of subjects: 70
Study 1589923 — intervention group
Group type: COMPARATOR
Intervention: Traditional scale dilatation (Control)
Number of subjects: 70
Study 6388247 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg moclobemide
Number of subjects: 38
Study 6388247 — intervention group
Group type: COMPARATOR
Intervention: 50 mg clomipramine
Number of subjects: 38
Study 31660240 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid mentor training approach (90-minute self-paced online module + workshops)
Number of subjects: 59
Study 31660240 — intervention group
Group type: COMPARATOR
Intervention: Control condition (two-page mentoring tip sheet)
Number of subjects: 59
Study 29265404 — intervention group
Group type: EXPERIMENTAL
Intervention: Invagination pancreaticojejunostomy
Number of subjects: 120
Study 29265404 — intervention group
Group type: COMPARATOR
Intervention: Duct-to-mucosa pancreaticojejunostomy
Number of subjects: 120
Study 29265404 — intervention group
Group type: EXPERIMENTAL
Intervention: Invagination pancreaticojejunostomy (in soft pancreas subgroup)
Number of subjects: 120
Study 29265404 — intervention group
Group type: COMPARATOR
Intervention: Duct-to-mucosa pancreaticojejunostomy (in soft pancreas subgroup)
Number of subjects: 120
Study 29265404 — intervention group
Group type: EXPERIMENTAL
Intervention: Invagination pancreaticojejunostomy (among patients with clinically relevant POPF)
Number of subjects: 120
Study 29265404 — intervention group
Group type: COMPARATOR
Intervention: Duct-to-mucosa pancreaticojejunostomy (among patients with clinically relevant POPF)
Number of subjects: 120
Study 26659199 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 mA
Number of subjects: 94
Study 26659199 — intervention group
Group type: COMPARATOR
Intervention: 0.5 mA
Number of subjects: 94
Study 25089881 — intervention group
Group type: EXPERIMENTAL
Intervention: Dimension cues indicating the relevant stimulus dimension (e.g., 'number')
Number of subjects: 0
Study 25089881 — intervention group
Group type: COMPARATOR
Intervention: Mapping cues providing information regarding both the relevant task identity and its category-to-key mapping (e.g., 'one three')
Number of subjects: 0
Study 25089881 — intervention group
Group type: EXPERIMENTAL
Intervention: Incongruent Stroop condition (name ink color of incongruent color names, high control demand)
Number of subjects: 0
Study 25089881 — intervention group
Group type: COMPARATOR
Intervention: Neutral Stroop condition (name color patches, low control demand)
Number of subjects: 0
Study 25089881 — intervention group
Group type: COMPARATOR
Intervention: Intermixed conditions of dimension cues and mapping cues
Number of subjects: 0
Study 25089881 — intervention group
Group type: COMPARATOR
Intervention: Intermixed conditions of incongruent and neutral Stroop stimuli
Number of subjects: 0
Study 21421689 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual task balance training (strength and balance training while performing cognitive tasks)
Number of subjects: 43
Study 21421689 — intervention group
Group type: COMPARATOR
Intervention: Strength and balance training only (control group)
Number of subjects: 43
Study 20105610 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial laparoscopic appendectomy
Number of subjects: 40
Study 20105610 — intervention group
Group type: COMPARATOR
Intervention: Initial nonoperative management (intravenous antibiotics with percutaneous drainage followed by interval laparoscopic appendectomy)
Number of subjects: 40
Study 17284750 — intervention group
Group type: EXPERIMENTAL
Intervention: Watercress supplementation (85 g raw watercress daily for 8 weeks)
Number of subjects: 60
Study 16124970 — intervention group
Group type: EXPERIMENTAL
Intervention: HA-coated tibial components
Number of subjects: 16
Study 16124970 — intervention group
Group type: COMPARATOR
Intervention: Uncoated tibial components
Number of subjects: 16
Study 11972998 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextromethorphan 100 mg
Number of subjects: 20
Study 11972998 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 10442377 — intervention group
Group type: EXPERIMENTAL
Intervention: UFT (300 to 400 mg/day for 2 years)
Number of subjects: 0
Study 10442377 — intervention group
Group type: EXPERIMENTAL
Intervention: UFT (600 mg/day)
Number of subjects: 0
Study 10442377 — intervention group
Group type: EXPERIMENTAL
Intervention: UFT (300 mg/day)
Number of subjects: 0
Study 8560358 — intervention group
Group type: EXPERIMENTAL
Intervention: Urovac bladder evacuator
Number of subjects: 0
Study 8560358 — intervention group
Group type: COMPARATOR
Intervention: Ellik evacuation
Number of subjects: 0
Study 8560358 — intervention group
Group type: COMPARATOR
Intervention: Toomey syringe
Number of subjects: 0
Study 2207297 — intervention group
Group type: EXPERIMENTAL
Intervention: Recainam (oral doses 54-208 mg kg-1 in mice)
Number of subjects: 0
Study 2207297 — intervention group
Group type: EXPERIMENTAL
Intervention: Recainam (oral doses 25-110 mg kg-1 in rats)
Number of subjects: 0
Study 2207297 — intervention group
Group type: EXPERIMENTAL
Intervention: Recainam (oral doses 50-100 mg kg-1 in rabbits)
Number of subjects: 0
Study 2207297 — intervention group
Group type: EXPERIMENTAL
Intervention: Recainam (i.v. doses 1-15 mg kg-1 in rhesus monkeys)
Number of subjects: 0
Study 2207297 — intervention group
Group type: EXPERIMENTAL
Intervention: Recainam (oral doses 6-60 mg kg-1 in dogs)
Number of subjects: 0
Study 2207297 — intervention group
Group type: EXPERIMENTAL
Intervention: Recainam (400-800 mg in humans)
Number of subjects: 0
Study 2207297 — intervention group
Group type: EXPERIMENTAL
Intervention: Recainam (single or multiple doses in dogs)
Number of subjects: 0
Study 2207297 — intervention group
Group type: EXPERIMENTAL
Intervention: Recainam (i.v. doses in rats and rabbits)
Number of subjects: 0
Study 2207297 — intervention group
Group type: EXPERIMENTAL
Intervention: Recainam (i.v. doses in dogs, rhesus monkeys, and humans)
Number of subjects: 0
Study 2207297 — intervention group
Group type: EXPERIMENTAL
Intervention: Recainam (in humans)
Number of subjects: 0
Study 2207297 — intervention group
Group type: EXPERIMENTAL
Intervention: Recainam (in rhesus monkeys)
Number of subjects: 0
Study 2207297 — intervention group
Group type: EXPERIMENTAL
Intervention: Recainam (in laboratory animals and humans)
Number of subjects: 0
Study 2207297 — intervention group
Group type: EXPERIMENTAL
Intervention: Recainam (in rodents, rabbits, dogs, rhesus monkeys, and humans)
Number of subjects: 0
Study 6456034 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous mass nylon suture with tight compression
Number of subjects: 302
Study 6456034 — intervention group
Group type: COMPARATOR
Intervention: Continuous mass nylon suture with normal tension
Number of subjects: 302
Study 30900152 — intervention group
Group type: EXPERIMENTAL
Intervention: Topically-administered haemocoagulase (batroxobin)
Number of subjects: 30
Study 30900152 — intervention group
Group type: COMPARATOR
Intervention: Normal Saline (control)
Number of subjects: 30
Study 27837415 — intervention group
Group type: EXPERIMENTAL
Intervention: Sexual intercourse 3-4 times/week with symptomatic treatment
Number of subjects: 56
Study 27837415 — intervention group
Group type: COMPARATOR
Intervention: Symptomatic treatment only (control group)
Number of subjects: 56
Study 25885280 — intervention group
Group type: EXPERIMENTAL
Intervention: 35 mg risedronate orally, once a week for 6 months postoperatively
Number of subjects: 73
Study 25885280 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73
Study 23313145 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment for prescription opioid dependence
Number of subjects: 0
Study 21360300 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone
Number of subjects: 0
Study 21360300 — intervention group
Group type: EXPERIMENTAL
Intervention: SRIH
Number of subjects: 0
Study 21360300 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine
Number of subjects: 0
Study 19665588 — intervention group
Group type: COMPARATOR
Intervention: Standard paper record (PR)
Number of subjects: 210
Study 19665588 — intervention group
Group type: EXPERIMENTAL
Intervention: PDA with dietary and physical activity software (PDA)
Number of subjects: 210
Study 19665588 — intervention group
Group type: EXPERIMENTAL
Intervention: PDA with the same software plus a customized feedback program (PDA + FB)
Number of subjects: 210
Study 19665588 — intervention group
Group type: EXPERIMENTAL
Intervention: Retention rate for the first cohort
Number of subjects: 210
Study 19139391 — intervention group
Group type: EXPERIMENTAL
Intervention: Aliskiren 150 mg
Number of subjects: 1124
Study 19139391 — intervention group
Group type: EXPERIMENTAL
Intervention: Aliskiren 300 mg
Number of subjects: 1124
Study 19139391 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide 12.5 mg
Number of subjects: 1124
Study 19139391 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1124
Study 16086932 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg/d
Number of subjects: 50
Study 16086932 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 50
Study 12118485 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid (Transamine)
Number of subjects: 46
Study 12118485 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 9925129 — intervention group
Group type: EXPERIMENTAL
Intervention: Mushrooms (C. tubaeformis) providing 14 microg ergocalciferol/d
Number of subjects: 27
Study 9925129 — intervention group
Group type: COMPARATOR
Intervention: Ergocalciferol supplement providing 14 microg/d
Number of subjects: 27
Study 9925129 — intervention group
Group type: COMPARATOR
Intervention: No supplementation
Number of subjects: 27
Study 7538881 — intervention group
Group type: EXPERIMENTAL
Intervention: 23-gauge needle
Number of subjects: 123
Study 7538881 — intervention group
Group type: COMPARATOR
Intervention: 27-gauge needle
Number of subjects: 123
Study 2150642 — intervention group
Group type: EXPERIMENTAL
Intervention: Isradipine
Number of subjects: 600
Study 2150642 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 600
Study 282069 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 9
Study 282069 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 9
Study 30366043 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive cystectomy
Number of subjects: 4760
Study 27265880 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirabegron (50 mg per day) for 8 weeks
Number of subjects: 70
Study 27265880 — intervention group
Group type: EXPERIMENTAL
Intervention: Imidafenacin (0.2 mg per day) for 8 weeks
Number of subjects: 70
Study 27265880 — intervention group
Group type: COMPARATOR
Intervention: Imidafenacin
Number of subjects: 70
Study 27265880 — intervention group
Group type: COMPARATOR
Intervention: Mirabegron
Number of subjects: 70
Study 24980414 — intervention group
Group type: EXPERIMENTAL
Intervention: Circumcision plus antibiotic, anti-inflammatory, and α-blocker therapy
Number of subjects: 774
Study 24980414 — intervention group
Group type: COMPARATOR
Intervention: Control group (medications only, no circumcision)
Number of subjects: 774
Study 23577702 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative, stereotypical images of obese targets
Number of subjects: 1251
Study 23577702 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive, nonstereotypical images of obese targets
Number of subjects: 1251
Study 23577702 — intervention group
Group type: EXPERIMENTAL
Intervention: African American female obese targets
Number of subjects: 1251
Study 23577702 — intervention group
Group type: COMPARATOR
Intervention: Caucasian targets
Number of subjects: 1251
Study 21562092 — intervention group
Group type: EXPERIMENTAL
Intervention: High-MUFA (HM) diet
Number of subjects: 448
Study 21562092 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat (LF) diet
Number of subjects: 448
Study 21562092 — intervention group
Group type: COMPARATOR
Intervention: High-SFA (HS) diet
Number of subjects: 448
Study 19235739 — intervention group
Group type: EXPERIMENTAL
Intervention: Olfactory training (12 weeks, twice daily exposure to four odors: phenyl ethyl alcohol, eucalyptol, citronellal, eugenol)
Number of subjects: 56
Study 19235739 — intervention group
Group type: COMPARATOR
Intervention: No olfactory training (control group)
Number of subjects: 56
Study 17008974 — intervention group
Group type: EXPERIMENTAL
Intervention: Orbofiban (oral glycoprotein IIb/IIIa inhibitor)
Number of subjects: 10392
Study 17008974 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10392
Study 17008974 — intervention group
Group type: EXPERIMENTAL
Intervention: Orbofiban
Number of subjects: 10392
Study 14711021 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept
Number of subjects: 0
Study 14711021 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab
Number of subjects: 0
Study 14711021 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab
Number of subjects: 0
Study 10761167 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel 75 mg PO QD for 10 days
Number of subjects: 24
Study 8826769 — intervention group
Group type: EXPERIMENTAL
Intervention: Music intervention
Number of subjects: 96